Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/01/2003WO2003035845A2 Salvador tumor suppressor gene
05/01/2003WO2003035836A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035698A1 Method for resistance of epilepsy by suppressing the function of alpha 1g protein
05/01/2003WO2003035694A2 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
05/01/2003WO2003035690A2 Hybrid and fusion polypeptide subunits of k+ channels
05/01/2003WO2003035688A2 Targeted thrombosis by tissue factor polypeptides
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035686A2 Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035683A2 Surfactant protein-d and atherosclerosis
05/01/2003WO2003035682A2 Peptides and protins binding to glu-pro motidfs, therapeutical compositions containing them and their applications
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035678A2 Sperm factor sequences
05/01/2003WO2003035675A1 Biologically active peptides and their use for repairing injured nerves
05/01/2003WO2003035667A2 Telomerase interference
05/01/2003WO2003035510A1 Transdermal/transmucosal patch packaging
05/01/2003WO2003035137A2 Method and apparatus for dispensing inhalator medicament
05/01/2003WO2003035111A1 Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
05/01/2003WO2003035110A1 Treating vascular disease by inhibiting toll-like receptor-4
05/01/2003WO2003035107A1 Enzyme inhibitors for inactivating allergens
05/01/2003WO2003035105A2 A synthetic chimeric fusion protein with immuno-therapeutic uses
05/01/2003WO2003035103A1 Anti-tumor chemotherapy by administration of cyclophosphamide and erythropoeitin
05/01/2003WO2003035102A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003WO2003035101A1 A method of treatment and agents useful for same
05/01/2003WO2003035100A1 Neuropilin as a novel therapeutic target for modulation of immune reponses
05/01/2003WO2003035099A1 Biphasic mixtures of glp-1 and insulin
05/01/2003WO2003035098A1 Method for re-sensitizing vancomycin resistant bacteria using agents which selectively cleave a cell wall depsipeptide
05/01/2003WO2003035096A1 Soluble proteins that inhibit cytokine signal transduction pathways
05/01/2003WO2003035095A1 Use of histamine to treat liver disease
05/01/2003WO2003035089A1 Preventives/remedies for foot and mouth disease
05/01/2003WO2003035083A1 Drug for treating a fibrotic disease through rna interfence
05/01/2003WO2003035082A1 Drug for inhibiting expression of a target gene
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035078A1 Combined use of catalytic antioxidants and glutathion or lipoic acid
05/01/2003WO2003035072A1 Use of flibanserin in the treatment of sexual disorders
05/01/2003WO2003035060A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003WO2003035055A1 Mch antagonists for the treatment of obesity
05/01/2003WO2003035051A2 The use of proton sequestering agents in drug formulations
05/01/2003WO2003035048A2 Methods for the treatment of osteoarthritis and compositions thereof
05/01/2003WO2003035033A1 Metallothioneine-containing liposomes
05/01/2003WO2003035028A1 Modulating charge density to produce improvements in the characteristics of spray-dried proteins
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003035010A2 Thymosin augmentation of genetic immunization
05/01/2003WO2003035004A2 Immunotherapy for reversing immune suppression
05/01/2003WO2003035002A2 Management of postoperative pain
05/01/2003WO2003034996A2 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
05/01/2003WO2003034993A2 Composition and method for growing, protecting, and healing tissues and cells
05/01/2003WO2003034990A2 Angiopoietins and methods of use thereof
05/01/2003WO2003034986A2 Regulation of mononuclear phagocyte stimulation
05/01/2003WO2003034985A2 Telomerase interference
05/01/2003WO2003034984A2 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003WO2003034938A2 Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
05/01/2003WO2003034903A2 Psma antibodies and protein multimers
05/01/2003WO2003026575A3 Molecules specific for npff receptors and uses thereof
05/01/2003WO2003014304A3 Protonic formulation
05/01/2003WO2003013578A8 Omoxin agonists and antagonists for use in the treatment of metabolic disorders
05/01/2003WO2003006483A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
05/01/2003WO2003004685A3 Soluble steroidal peptides for nucleic acid delivery
05/01/2003WO2003004680A3 Atherosclerosis susceptibility gene locus 1 (athsq1) and 2 (athsq2)
05/01/2003WO2003002152A3 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
05/01/2003WO2003000777A3 Multi-arm block copolymers as drug delivery vehicles
05/01/2003WO2003000277A3 Antimicrobial peptides
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002098444A3 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
05/01/2003WO2002098287A3 A high throughput biological heart rate monitor that is molecularly determined
05/01/2003WO2002095053A3 Antisense modulation of src-c expression
05/01/2003WO2002090553A3 Recombinant fusion proteins and the trimers thereof
05/01/2003WO2002090519A3 Mutant p21?cip1/waf1¿ and cell growth control
05/01/2003WO2002089835A3 Pharmaceutical dosage form of amorphous nelfinavir mesylate
05/01/2003WO2002088183A3 G-protein coupled receptor
05/01/2003WO2002083734A3 Modified calcitonin
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002081520A3 Single chain dimeric polypeptides derived from the vegf family
05/01/2003WO2002081513A3 Disease-associated protein
05/01/2003WO2002076483A3 Bacteriophage preparation
05/01/2003WO2002076391A3 Microbial feeds for aquaculture and agriculture
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002072755A3 Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27
05/01/2003WO2002070548A3 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
05/01/2003WO2002067897A3 In-situ gel formation of pectins
05/01/2003WO2002066645A3 Mutant pro-neurotrophin with improved activity
05/01/2003WO2002064783A3 Novel cofactors of the estrogen receptor beta and methods of use
05/01/2003WO2002063007A3 TIMM8b-RELATED PROTEIN
05/01/2003WO2002059356A3 Method for screening compounds for activity in treating an osteoclast related bone disease
05/01/2003WO2002053741A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/01/2003WO2002053017A3 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
05/01/2003WO2002046433A3 Tnf-inducible promotors and methods for using them
05/01/2003WO2002044113A9 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
05/01/2003WO2002042460A3 Compositions and methods relating to colon specific genes and proteins
05/01/2003WO2002039995A3 Combination therapy for estrogen-dependent disorders
05/01/2003WO2002038600A3 C. elegans genes involved in viability and/or reproduction and uses thereof
05/01/2003WO2002036783A3 Regulation of human histone deacetylase
05/01/2003WO2002034910A3 Method for modulating granzyme b uptake and for identifying modulators thereof
05/01/2003WO2002034282A3 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
05/01/2003WO2002031149A9 Polyvalent cation-sensing receptor proteins in aquatic species
05/01/2003WO2002013873A3 P97-active agent conjugates and their methods of use
05/01/2003WO2002010124A3 Salt forms of an hiv protease inhibitor
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003WO2002000244A3 Protein mixtures for wound healing
1 ... 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 ... 3163